Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MGMT unmethylation
i
Other names:
MGMT, Methylated-DNA--protein-cysteine methyltransferase, 6-O-methylguanine-DNA methyltransferase, O-6-methylguanine-DNA-alkyltransferase
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4255
Related biomarkers:
Expression
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MGMT unmethylation
Glioma
MGMT unmethylation
Glioma
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 4 days (New B)
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 4d
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 4 days
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 4 days - (New B)
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
temozolomide
Sensitive: B - Late Trials
temozolomide
Sensitive
:
B
temozolomide
Sensitive: B - Late Trials
temozolomide
Sensitive
:
B
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
nivolumab + ipilimumab
Sensitive
:
C3
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
cemiplimab + INO-5401 + INO-9012
Sensitive: C3 – Early Trials
cemiplimab + INO-5401 + INO-9012
Sensitive
:
C3
cemiplimab + INO-5401 + INO-9012
Sensitive: C3 – Early Trials
cemiplimab + INO-5401 + INO-9012
Sensitive
:
C3
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
VAL-083
Sensitive: C3 – Early Trials
VAL-083
Sensitive
:
C3
VAL-083
Sensitive: C3 – Early Trials
VAL-083
Sensitive
:
C3
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
pembrolizumab
Resistant: C3 – Early Trials
pembrolizumab
Resistant
:
C3
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
NOX-A12
Sensitive: C3 – Early Trials
NOX-A12
Sensitive
:
C3
NOX-A12
Sensitive: C3 – Early Trials
NOX-A12
Sensitive
:
C3
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
temozolomide + ABT-888
Sensitive: C3 – Early Trials
temozolomide + ABT-888
Sensitive
:
C3
temozolomide + ABT-888
Sensitive: C3 – Early Trials
temozolomide + ABT-888
Sensitive
:
C3
MGMT unmethylation
Glioblastoma
MGMT unmethylation
Glioblastoma
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
abemaciclib
Sensitive: C3 – Early Trials
abemaciclib
Sensitive
:
C3
MGMT unmethylation
Glioma
MGMT unmethylation
Glioma
nivolumab + aglatimagene besadenovec
Sensitive: C3 – Early Trials
nivolumab + aglatimagene besadenovec
Sensitive
:
C3
nivolumab + aglatimagene besadenovec
Sensitive: C3 – Early Trials
nivolumab + aglatimagene besadenovec
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login